Amgen Inc. $AMGN Shares Purchased by New England Research & Management Inc.

New England Research & Management Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 19.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,215 shares of the medical research company’s stock after buying an additional 2,335 shares during the period. Amgen comprises about 2.3% of New England Research & Management Inc.’s holdings, making the stock its 8th biggest position. New England Research & Management Inc.’s holdings in Amgen were worth $5,992,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Wellington Altus USA Inc. lifted its stake in Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares during the last quarter. Tower View Wealth Management LLC grew its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the period. Nvwm LLC grew its holdings in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new stake in Amgen in the second quarter worth $36,000. Finally, Steph & Co. purchased a new stake in Amgen in the third quarter worth $42,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Amgen Stock Performance

Amgen stock traded down $1.54 during mid-day trading on Friday, reaching $432.49. The company’s stock had a trading volume of 2,567,027 shares, compared to its average volume of 3,127,974. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03. The company has a market capitalization of $233.82 billion, a P/E ratio of 26.88, a PEG ratio of 3.18 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm’s fifty day moving average price is $415.54 and its two-hundred day moving average price is $374.76.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AMGN. Mizuho boosted their target price on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Robert W. Baird increased their price target on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. HSBC lowered Amgen from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Sanford C. Bernstein boosted their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Finally, Piper Sandler boosted their price objective on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $387.93.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.